Patents by Inventor Laura Lauener
Laura Lauener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250073308Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 18, 2024Publication date: March 6, 2025Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umaña, Inja Waldhauer
-
Publication number: 20240425561Abstract: Provided are mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, provided are polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. Also provided are methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: April 12, 2024Publication date: December 26, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Alejandro CARPY GUTIERREZ CIRLOS, Laura CODARRI DEAK, Greta DURINI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Johann KOLL, Laura LAUENER, Ekkehard MOESSNER, Valeria NICOLINI, Cindy SCHULENBURG, Pablo UMAÑA
-
Publication number: 20240269277Abstract: Provided are immunoconjugates for use in the treatment of cancer, particularly wherein the immunoconjugates comprise a mutant interleukin 7 polypeptide and an antibody that binds to PD-1. In addition, provided are the use of such immunoconjugates and methods of treating cancer comprising administering said immunoconjugates.Type: ApplicationFiled: April 12, 2024Publication date: August 15, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Laura CODARRI DEAK, Greta DURINI, Anne FREIMOSER-GRUNDSCHOBER, Christian KLEIN, Laura LAUENER, Ekkehard MOESSNER, Valeria NICOLINI, Cindy SCHULENBURG, Pablo UMAÑA
-
Patent number: 12023368Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: GrantFiled: June 30, 2022Date of Patent: July 2, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Publication number: 20240043535Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: December 16, 2022Publication date: February 8, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
-
Publication number: 20230192795Abstract: The present invention generally relates to mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: April 13, 2021Publication date: June 22, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Anne Freimoser-Grundschober, Christian Klein, Laura Lauener, Ekkehard Moessner, Cindy Schulenburg, Pablo Umaña, Eleni Maria Varypataki
-
Publication number: 20230134606Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 30, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Publication number: 20230071733Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 7, 2022Publication date: March 9, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Patent number: 11413331Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: GrantFiled: April 2, 2018Date of Patent: August 16, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Publication number: 20180326011Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: April 2, 2018Publication date: November 15, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Publication number: 20180326010Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: April 2, 2018Publication date: November 15, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer